Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-Associated Antigens (Ovarian Cancer) (TAA)
- Target
- TAA
- Molecular classification
- Glycoprotein, Receptor, Cell adhesion molecule, Receptor tyrosine kinase, Transcription factor, Tumor suppressor protein, Cell surface protein
01
Overview
Tumor-associated antigens (TAAs) in ovarian cancer are molecules overexpressed or uniquely presented on the surface of ovarian tumor cells compared to normal tissues. They serve as biomarkers for diagnosis, prognosis, and targets for immunotherapy. Major TAAs include MUC16 (CA125), FOLR1, EPCAM, MUC1, Her2/neu, WT1, p53, and Mesothelin. TAAs can elicit immune responses and are being explored as targets for CAR-T cell therapies and other immunotherapeutic approaches.
02
Mechanism of action
Varies depending on the specific TAA. For example, antibodies may block receptor signaling or mediate antibody-dependent cellular cytotoxicity (ADCC). CAR-T cells kill tumor cells expressing the target antigen.
03
Biological functions
Cell adhesionSignal transductionImmune responseCell proliferationTumor growthCell-cell interaction
04
Disease associations
CancerOvarian CancerTumorigenesis
05
Safety considerations
Off-target toxicity of immunotherapiesCytokine release syndrome (CRS) with CAR-T cell therapyOn-target, off-tumor effects
06
Interacting drugs
Antibody-drug conjugates (ADCs) targeting specific TAAs
1 more in the full profile.
07
Biomarkers
CA125 (MUC16) - diagnostic and monitoringFOLR1 - patient selection for targeted therapiesMesothelin - prognosticWT1 - prognosticp53 - prognostic
Beyond the preview
Go deeper on Tumor-Associated Antigens (Ovarian Cancer) (TAA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Associated Antigens (Ovarian Cancer) (TAA).